Recent Updates
Recently added Catalysts

MZE829

Phase 2

Proteinuric Kidney Disease | Small molecule | Nephrology |Maze Therapeutics, Inc.|Last Updated: Apr 17, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment56
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06830629A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseasePHASE2 RECRUITING 56 — — Feb 5, 2025Sep 1, 2026Apr 17, 202681 United States, France +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and tolerability as assessed by incidence of adverse events (AEs)
Day 1 to Week 12
Secondary Endpoints
Percent participants with ≥30% reduction from baseline in UACR at Week 12
Day 1 to Week 12
Geometric mean plasma drug concentrations
Day 1 to Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
MZE829EXPERIMENTALCohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes
Interventions
NameTypeDescription
MZE829DRUGCapsules for oral administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 68 Years
SexALL
Healthy VolunteersNo
Study Sites81

Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical...

Countries:United StatesFranceUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06830629primaryCompletionDate: changed
LOWMay 24, 2026NCT06830629studyFirstPostDate: changed